Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)
Latest Information Update: 26 Sep 2022
At a glance
- Drugs Miglustat (Primary)
- Indications Gangliosidoses; Tay-Sachs disease
- Focus Therapeutic Use
- Acronyms Syner-G
- 18 Mar 2021 Status changed from recruiting to discontinued, due to efficacy.
- 19 Jun 2018 Planned End Date changed from 1 Mar 2019 to 31 Aug 2019.
- 19 Jun 2018 Planned primary completion date changed from 1 Mar 2019 to 31 Aug 2019.